Reposted by @manasib33.bsky.socialSwapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 26/03/2026A KDIGO commentary on B Cell and Complement guided therapy in IgAN www.kidney-international.org/article/S008... in Kidney Int Perfectly timed for #NephMadness (and this will be the champion) 1139
manasib33.bsky.social @manasib33.bsky.social · 25/03/2026@nephmadness.bsky.social Our first ever TPMG nephrology #nephmadness2026 party! Had fun and learnt a lot from all the great write ups! IgAN B cell targets is the winner for us all the way! 001
Reposted by @manasib33.bsky.socialBrendon Neuen @brendonneuen.bsky.social · 07/06/2025How will the #CONFIDENCE trial shape practice in #CKD + #T2D? I spoke with PI, Rajiv Agarwal, after his #ERA25 late-breaker on why a sequential approach may be doing our patients a disservice Full episode: hcplive.com/view/kidney-... #KidneyCompass #SGLT2i #finerenone 063
Reposted by @manasib33.bsky.socialSwapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 07/06/2025As Nephrin and anti-Nephrin goes mainstream, a call to standardize assays www.kidney-international.org/article/S008... in @kidneyint.bsky.social (who need to up their visual abstract game) #NephSky 0186
Reposted by @manasib33.bsky.socialAmerican Journal of Kidney Diseases @ajkd.bsky.social · 10/03/2025#NephMadness Commentary on Hemodialysis Region by Mariana Murea: The Future of Dialysis Personalization bit.ly/NM25MureaCommentarybit.ly#NephMadness 2025: Hemodialysis – The Future of Dialysis PersonalizationSubmit your picks! | @NephMadness | @nephmadness.bsky.social | NephMadness 2025 Mariana Murea @MarianaMurea Mariana Murea is an Associate Professor, nephrologist, and clinician-scientist at Wake … 177
Reposted by @manasib33.bsky.socialMatthew Sparks @nephrosparks.bsky.social · 10/03/2025Next #NephMadness podcrawl on the resistant hypertension region from the the Curbsiders with region expert @jordybc.bsky.social podcasts.apple.com/us/podcast/t...podcasts.apple.com#474 Resistant Hypertension the Next FrontierPodcast Episode · The Curbsiders Internal Medicine Podcast · 03/10/2025 · 1h 17m 1148
Reposted by @manasib33.bsky.socialMatthew Sparks @nephrosparks.bsky.social · 10/03/2025The 2nd ASN Kidney Health Guidance on the Outpatient Management of Patients with Dialysis-Requiring AKI @asnpublications.bsky.social in JASN Listen to the podcast on ASN Kidney Translation with @vijayanmd.bsky.social and Dr Heung here www.asn-online.org/media/podcas... 0178
Reposted by @manasib33.bsky.socialSwapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 06/03/2025Announcing the #NephJC internship, @nephjc.bsky.social and @kireports.bsky.social joining forces www.nephjc.com/intern-app for details and to apply! #NephSkynephjc.comNephJC Editorial Internship — NephJC 04236
Reposted by @manasib33.bsky.socialAmerican Journal of Kidney Diseases @ajkd.bsky.social · 05/03/2025The #AJKDBlog homepage has been transformed to #NephMadness HQ! 2025 topics include: - Resistant Hypertension - Obesity - Green House - Minimal Change Disease - Disaster Nephrology - Genetics - Hemodialysis - CAR-T for Kidney Disease Happy reading: AJKDBlog.org 186
Reposted by @manasib33.bsky.socialAlex Chang, MD @alexchangmd.bsky.social · 06/03/2025Great Geisinger #nephmadness night! Note Kartik’s @kkalra.bsky.social virtual Madness bandanna. No one’s happy about our surprise dark horse winner - incremental dialysis! 2189
Reposted by @manasib33.bsky.socialSwapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 04/03/2025Say No to #HydrANCAzine @juancarlosqvelez.bsky.social I can’t remember when I last started a patient on it 🤔 #NephMadness 181
Reposted by @manasib33.bsky.socialAlex Chang, MD @alexchangmd.bsky.social · 02/03/2025Awesome #nephmadness write up about resistant #hypertension renal denervation vs. novel drugs @stephanietr612.bsky.social @jordybc.bsky.social and visual abstracts @nephroseeker.medsky.social …And troubling AI-generated kidney art with tablet-shaped electroshockers i@littlebiggloms.bsky.social 1128
manasib33.bsky.social @manasib33.bsky.social · 03/03/2025Thank you #Nephmadness for this opportunity to write for the Hemodialysis region! HDF has a huge potential and incremental HD has many of its own advantages, who will win this region? A tough match up indeed! 074
manasib33.bsky.social @manasib33.bsky.social · 03/03/2025So many interesting topics, so much to learn as usual! Let’s go #nephmadness 2025! 062
Reposted by @manasib33.bsky.socialJoel Topf @kidneyboy.bsky.social · 07/01/2025Here is a link to all of the Top Stories on RFN www.renalfellow.org/tag/top-stor...renalfellow.orgRenal Fellow NetworkFor Fellows, By Fellows 064
Reposted by @manasib33.bsky.socialGates Colbert, MD FASN @doctorgates.bsky.social · 07/01/2025www.instagram.com/p/DEiaAmDPtE... My favorite post by NephJC each year. 044
![Figure 1 Therapeutic targets and positioning of treatments in IgA nephropathy (IgAN). Reflecting our latest understanding, treatments should target IgAN-specific drivers for nephron loss (Hits 1-3, Hit 4) and generic response to IgAN-induced nephron loss. Drugs targeting the IgAN-specific drivers for nephron loss likely act on different mechanisms of the 4-hit hypothesis. Triangles denote that a drug class most likely exerts its key actions on either Hits 1-3 or Hit 4 but may target all hits to a variable extent as indicated by their lengths of the triangle. Nefecon, APRIL inhibitors, and dual APRIL-BAFF inhibitors are shown as having a predominant effect on the production of pathogenic forms of IgA and IgA containing immune complexes (IgA-ICs) [Hits 1-3] while systemic glucocorticoids and complement inhibitors are shown as having a predominant anti-inflammatory effect on IgA-IC mediated kidney injury [Hit 4]. Interventions to manage the generic response to IgAN-induced nephron loss include lifestyle modifications, RASi or DEARA use with or without SGLT2i, or use of a DEARA or a combination of ERA and RASi. Additional strategies may also include the use of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors in select patients. The drugs listed here do not imply a recommended ranking or delivery sequence. APRIL, a proliferation-inducing ligand; BAFF, B cell–activating factor; DEARA, dual endothelin angiotensin receptor antagonist; ERA, endothelin type A receptor antagonist; RASi, renin-angiotensin system inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:33h4q6nw674jdcwfxaq2m2nl/bafkreidryzyepbhcxh4g7cjglwmmk6tfgyxmujh55el3ey76ki4zp4qa5i)
